Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Waymo Explores Split With Uber - FT
• Creative Medical Technology (CELZ) files for 5.58M share offering by selling stockholders
• American Express down 2% in premarket trade after Q2 revenue miss offsets EPS beat